CanDiag Inc.
Blood test for detecting early-stage breast cancer
This article was originally published in Start Up
Executive Summary
CanDiag Inc. spun out of the University of North Carolina at Charlotte to develop an antibody-based blood test for detecting early-stage breast cancer. The start-up will first use the technology to develop a blood test for breast cancer recurrence, but the ultimate goal is to develop a test that can be used for women who have an abnormal mammogram; the test would be performed in lieu of additional expensive imaging studies and before performing biopsies.